HEALTHCARE
{ HEALTHCARE INNOVATION } MICHAEL BABICH
WILLIAM GARTNER
President and CEO INSYS Therapeutics, Inc. insysrx.com
Babich was appointed CEO in March 2011. From March 2007 until November 2010, Babich served as the COO and a director of INSYS Pharma, Inc., a wholly-owned subsidiary of INSYS, which is responsible for the initial development of Dronabinol SG Capsule and many of its product candidates, including Subsys and other dronabinol product candidates. Babich’s leadership led INSYS to the best initial public offering of 2013. INSYS is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. INSYS currently markets two products: Subsys® (fentanyl sublingual spray), and a generic version of Dronabinol (THC) capsules. The Company recently submitted a new drug application to the FDA.
President and CEO Global Cancer Diagnostics globalcancerdx.com
Gartner has founded a number of laboratory companies focusing on medical diagnostics and environmental marketing. Most recently, one of those companies developed a blood test for Alzheimer’s disease in collaboration with the Paul Fleischig Institute at the University of Leipzig. In the last year, Gartner founded Global Cancer Diagnostics Inc. to commercialize a blood test for lung cancer that detects the disease in stages 1 and 2, when it can be treated with much higher survivability rates. The test will be sold through physicians and directly to consumers in the 27 states that allow direct-toconsumer diagnostics. The most remarkable features are the ROC Accuracy of the test at 97.2 percent and its price at $99, eliminating the need for insurance reimbursement in most cases.
GORDON GRADO, MD, PHD Medical director Southwest Oncology Centers swoncology.net
Grado is director of Southwest Oncology Centers in Arizona and Latin America. While chairman of radiation oncology at Mayo Clinic, he developed the first interactive prostate brachytherapy program utilizing biplane ultrasound and
TJ JOHNSON
President and CEO HTG Molecular Diagnostics, Inc. htgmolecular.com Johnson joined HTG Molecular Diagnostics in 2008 as CEO and has led the company’s transition from a boutique research company to a growing personalized healthcare-based company. Johnson has lead the efforts to establish the key business strategies, hire a management team with more than 200 years of combined diagnostic experience and recently completed an initial public offering (IPO). Toughest challenge: “There have been many, but the challenge of financing HTG through its business transition, including our recent IPO, has been the greatest. Vision, communication and perseverance are key in any challenging endeavor.” Business advice: “Surround yourself with the smartest, most talented people you can. Smart, talented people figure it out and attract other smart, talented people.”
88 ABL | Nominate at azBIGmedia.com
fluoroscopy and programs worldwide. He has held academic appointments, delivered hundreds of presentations and authored peer-reviewed manuscripts. Toughest challenge: “Recruiting and developing the best medical team of professionals that could handle the challenges of patient care, create new approaches to radiation delivery, and could help teach and train these new approaches was the challenge. This was overcome by looking for the best staff at every presentation and recruiting globally.”
RUSS YELTON CEO Pinnacle Transplant Technologies pinnacletransplant.com
Yelton provides executive level leadership to a rapidly expanding tissue bank and medical device company. Pinnacle Transplant Technologies is a multi-service tissue bank dedicated to ethical participation in the donate life process. U.S. Food and Drug Administration registered and American Association of Tissue Banks accredited, Pinnacle only works with federally chartered Organ Procurement Organizations to safeguard its employees, provide superior allografts for
transplantation and assure reverence to its donor families. Prior to joining Pinnacle Transplant Technologies, Yelton was president and CEO of the Northern Arizona Center for Entrepreneurship and Technology in Flagstaff, a business incubation program that assists companies with commercializing their technologies.